A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes

What is the central question of this study? The mechanism by which PAI‐1R reduces proteinuria has not been previously explored. What is the main finding and its importance? Using cultured podocytes and diabetic db/db mice, we show that, similar to the effects of transforming growth factor‐β1, PAI‐1 directly injures podocytes. Reducing the increased PAI‐1 activity by PAI‐1R in diabetic db/db mice, in fact, reduces podocyte injury, thereby reducing albuminuria. Therefore, PAI‐1R may provide an additional therapeutic effect in slowing progression of diabetic nephropathy by maintaining podocyte integrity.

[1]  A. Ghosh,et al.  PAI‐1 in tissue fibrosis , 2012, Journal of cellular physiology.

[2]  V. Pérez,et al.  Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  B. Klanke,et al.  Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage , 2011, Journal of hypertension.

[4]  A. Fornoni.  Proteinuria, the podocyte, and insulin resistance. , 2010, The New England journal of medicine.

[5]  N. Brown.  Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors , 2010, Therapeutic advances in cardiovascular disease.

[6]  N. Kohno,et al.  Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis , 2010, Thorax.

[7]  K. Kimura,et al.  Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  D. Lawrence,et al.  Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. , 2009, American journal of physiology. Renal physiology.

[9]  P. Epstein,et al.  Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.

[10]  P. McKeown-Longo,et al.  PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the αvβ5 and α5β1 integrins , 2008, Journal of Cell Science.

[11]  D. Lawrence,et al.  A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.

[12]  Youhua Liu,et al.  Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. , 2008, The American journal of pathology.

[13]  G. Wolf,et al.  Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. , 2008, Current diabetes reviews.

[14]  N. Noble,et al.  PAI-1 as a target in kidney disease. , 2007, Current drug targets.

[15]  W. Border,et al.  Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. , 2007, Kidney international.

[16]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease , 2007, Diabetologia.

[17]  A. Fogo,et al.  Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. , 2006, Journal of the American Society of Nephrology : JASN.

[18]  D. Lawrence,et al.  Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. , 2006, Kidney international.

[19]  Hiroshi Kawachi,et al.  Role of podocyte slit diaphragm as a filtration barrier (Review Article) , 2006, Nephrology.

[20]  S. Shankland,et al.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis. , 2006, Kidney international.

[21]  S. Chua,et al.  Plasminogen Activator Inhibitor-1 Deficiency Has Renal Benefits but Some Adverse Systemic Consequences in Diabetic Mice , 2006, Nephron Experimental Nephrology.

[22]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. , 2005, Kidney international.

[23]  H. Parving,et al.  Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. , 2005, Kidney international.

[24]  S. Shankland,et al.  Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  Roger E Bumgarner,et al.  Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. , 2005, Kidney international.

[26]  W. Hsueh,et al.  Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. , 2005, Kidney international.

[27]  R. Kalluri,et al.  Induction of B7-1 in podocytes is associated with nephrotic syndrome. , 2004, The Journal of clinical investigation.

[28]  D. Lawrence,et al.  A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. , 2003, The Journal of clinical investigation.

[29]  Y. Kanwar,et al.  Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. , 2003, The Journal of clinical investigation.

[30]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. , 2003, Journal of the American Society of Nephrology : JASN.

[31]  C. Marcantoni,et al.  Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. , 2002, Kidney international.

[32]  P. Thompson,et al.  Regulation of human lung fibroblast phenotype and function by vitronectin and vitronectin integrins. , 2001, Journal of cell science.

[33]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[34]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[35]  S. Hong,et al.  mRNA expression of urokinase and plasminogen activator inhibitor‐1 in human crescentic glomerulonephritis , 2001, Histopathology.

[36]  A. Eddy,et al.  PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. , 2001, Kidney international.

[37]  D. Lawrence,et al.  Inhibition of Angiogenesis in Vivo by Plasminogen Activator Inhibitor-1* , 2001, The Journal of Biological Chemistry.

[38]  D. Lawrence,et al.  Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin* , 2000, The Journal of Biological Chemistry.

[39]  L. Gesualdo,et al.  Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  A. Sharpe,et al.  T-cell stimulation: an abundance of B7s , 1999, Nature Medicine.

[41]  J. Allison,et al.  Costimulatory regulation of T cell function. , 1999, Current opinion in cell biology.

[42]  L. Gold,et al.  Increased levels of transforming growth factor-beta in HIV-associated nephropathy. , 1999, Kidney international.

[43]  C. Nast,et al.  Expression of transforming growth factor-β isoforms in human glomerular diseases , 1996 .

[44]  C. Nast,et al.  Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. , 1995, Journal of the American Society of Nephrology.

[45]  J. Shore,et al.  Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic interaction chromatography , 1995 .

[46]  E. Kruithof,et al.  Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. , 1990, Clinical nephrology.

[47]  Bancha Satirapoj,et al.  Nephropathy in Diabetes , 2023, Experimental and Clinical Endocrinology & Diabetes.

[48]  P. Carmeliet,et al.  Modification of kidney barrier function by the urokinase receptor , 2008, Nature Medicine.

[49]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[50]  C. Nast,et al.  Expression of transforming growth factor-beta isoforms in human glomerular diseases. , 1996, Kidney international.

[51]  Y. Eguchi,et al.  Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. , 1993, The American journal of pathology.